Skip to content
Skip to navigation
Skip to footer

Press Releases

View global media contacts

Latest

AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion
6 July 2021
Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose
28 June 2021
AstraZeneca Appoints Dr. Susan Galbraith as Executive Vice President, Oncology Research & Development
28 June 2021
Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease
28 June 2021
Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants at high risk of RSV
28 June 2021
First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated
27 June 2021
Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
24 June 2021
Orpathys approved in China for patients with lung cancer and MET gene alterations
23 June 2021
Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas
22 June 2021
AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe
18 June 2021

previous
3
4
5
6
7
8
9
28
next

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive